Prognostic factors and 5-year overall survival in older adults (≥60 years) with Hodgkin lymphoma in Latin America: A multicenter cohort study
Abstract Background: Data on outcomes and prognostic factors in older adults with Hodgkin lymphoma (HL) from Latin America remain scarce. We aimed to characterize overall survival (OS) and identify clinical predictors of 5-year OS in this population. Methods: We analyzed a multicenter cohort of 241 HL patients, treated with ABVD regimen, aged ≥60 years from Latin America. Clinical, laboratory, and treatment variables were harmonized and cleaned for analysis. Five-year OS was estimated using Kaplan-Meier methods. Univariate Cox regression models tested associations between OS and covariates including age, Ann Arbor stage, lymphocyte count, hemoglobin, and PET response. Variables significant in univariate analyses and clinically relevant were included in a multivariable Cox proportional hazards model. Results: Median age was 68 years (range 60–88), with 61% males. The 5-year OS was 65.2% (95% CI: 58.0–73.3%). In univariate analysis, increasing age (HR per year 1.06, p=0.0018), advanced Ann Arbor stage, lymphopenia (<600/mm³ or <8%; HR=0.43, p=0.007), and anemia (Hb <10 g/dL; HR=0.40, p=0.001) were significantly associated with worse OS. PET response was not significantly associated with OS. In the multivariable model (n=154, 38 events), older age (HR 1.08 per year, p=0.0007), advanced Ann Arbor stage (notably stages IIA, IIIA, IIIB; p<0.05), and lymphopenia (HR 0.39, p=0.023) remained independent predictors of inferior 5-year OS. Hemoglobin was not independently significant after adjustment. Conclusions: Older age, advanced disease stage, and low lymphocyte count independently predict poorer survival in older Latin American patients with HL. These factors should be incorporated into risk stratification and management decisions to improve outcomes. Further research is needed to optimize therapies tailored for this population. Keywords: Hodgkin lymphoma, elderly, Latin America, survival, prognostic factors
Authors
- miguel Nicolas lopez Caceres
- Sofía Rivarola (ORCID: https://orcid.org/0000-0002-3302-5154)
- Maria Enciso Arrua
- Rosario Jiménez (ORCID: https://orcid.org/0000-0003-3872-2669)
- Alfredo Quiroz (ORCID: https://orcid.org/0000-0003-4268-9881)
- Jorge J. Castillo (ORCID: https://orcid.org/0000-0001-9490-7532)
- Alana Von Glasenapp (ORCID: https://orcid.org/0000-0002-1805-5830)
- Julio Fernández-Águila
- Javier Retamales (ORCID: https://orcid.org/0000-0001-7051-0362)
- Bryan Valcárcel (ORCID: https://orcid.org/0000-0003-3853-2603)
- Fernando Warley (ORCID: https://orcid.org/0000-0002-2589-8190)
- Germán Stemmelin
- Luis Mario Villela Martínez
- Brady Beltrán (ORCID: https://orcid.org/0000-0003-4469-3817)
- Denisse Castro (ORCID: https://orcid.org/0000-0001-5330-9309)
- Victoria Irigoín (ORCID: https://orcid.org/0000-0002-6816-666X)
- M. P. Orlova (ORCID: https://orcid.org/0000-0003-4954-452X)
- Luis Malpica (ORCID: https://orcid.org/0000-0002-7082-1846)
- Henry Idrobo Quintero
- Carolina Oliver (ORCID: https://orcid.org/0000-0002-7782-2024)
- Marialejandra Torres Viera (ORCID: https://orcid.org/0000-0001-6188-8494)
- Virginia Lema Spinelli
- Amy Alvarenga Tanii
Institutions
- Hospital Británico (UY)
- The University of Texas MD Anderson Cancer Center (US)
- Hermanos Ameijeiras Hospital (CU)
- Clínica Alemana (CL)
- Hospital Italiano de Buenos Aires (AR)
- Bank of Mexico (MX)
- Hospital Nacional Cayetano Heredia (PE)
- Dana-Farber Cancer Institute (US)
- Gobierno de Chile (CL)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Hospital Dr. Gustavo Fricke (CL)
- Hospital Británico de Buenos Aires (AR)
- Asociación Colombiana de Gastroenterología (CO)
- IPS Central (PY)
- Universidad de Montevideo (UY)
- Universidad Central de Venezuela (VE)
Publication Details
- Journal
- Blood
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1182/blood-2025-7145
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00